Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.47
NUVA's Cash to Debt is ranked lower than
76% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. NUVA: 0.47 )
Ranked among companies with meaningful Cash to Debt only.
NUVA' s Cash to Debt Range Over the Past 10 Years
Min: 0.47  Med: 0.89 Max: No Debt
Current: 0.47
Equity to Asset 0.41
NUVA's Equity to Asset is ranked lower than
79% of the 298 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. NUVA: 0.41 )
Ranked among companies with meaningful Equity to Asset only.
NUVA' s Equity to Asset Range Over the Past 10 Years
Min: 0.36  Med: 0.49 Max: 0.93
Current: 0.41
0.36
0.93
Interest Coverage 3.15
NUVA's Interest Coverage is ranked lower than
88% of the 192 Companies
in the Global Medical Devices industry.

( Industry Median: 45.13 vs. NUVA: 3.15 )
Ranked among companies with meaningful Interest Coverage only.
NUVA' s Interest Coverage Range Over the Past 10 Years
Min: 0.65  Med: 3.19 Max: 9999.99
Current: 3.15
0.65
9999.99
F-Score: 5
Z-Score: 2.89
M-Score: -2.65
WACC vs ROIC
6.76%
6.85%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 11.48
NUVA's Operating margin (%) is ranked higher than
76% of the 305 Companies
in the Global Medical Devices industry.

( Industry Median: 2.61 vs. NUVA: 11.48 )
Ranked among companies with meaningful Operating margin (%) only.
NUVA' s Operating margin (%) Range Over the Past 10 Years
Min: -34.77  Med: 2.72 Max: 17.15
Current: 11.48
-34.77
17.15
Net-margin (%) 3.10
NUVA's Net-margin (%) is ranked higher than
55% of the 305 Companies
in the Global Medical Devices industry.

( Industry Median: 0.86 vs. NUVA: 3.10 )
Ranked among companies with meaningful Net-margin (%) only.
NUVA' s Net-margin (%) Range Over the Past 10 Years
Min: -48.84  Med: -0.84 Max: 16.37
Current: 3.1
-48.84
16.37
ROE (%) 3.86
NUVA's ROE (%) is ranked higher than
55% of the 299 Companies
in the Global Medical Devices industry.

( Industry Median: 0.98 vs. NUVA: 3.86 )
Ranked among companies with meaningful ROE (%) only.
NUVA' s ROE (%) Range Over the Past 10 Years
Min: -40.87  Med: -1.05 Max: 21.43
Current: 3.86
-40.87
21.43
ROA (%) 1.93
NUVA's ROA (%) is ranked higher than
56% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: -0.34 vs. NUVA: 1.93 )
Ranked among companies with meaningful ROA (%) only.
NUVA' s ROA (%) Range Over the Past 10 Years
Min: -35.8  Med: -0.53 Max: 10.76
Current: 1.93
-35.8
10.76
ROC (Joel Greenblatt) (%) 20.18
NUVA's ROC (Joel Greenblatt) (%) is ranked higher than
71% of the 319 Companies
in the Global Medical Devices industry.

( Industry Median: 4.07 vs. NUVA: 20.18 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NUVA' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -82.47  Med: 7.27 Max: 47.3
Current: 20.18
-82.47
47.3
Revenue Growth (3Y)(%) 3.40
NUVA's Revenue Growth (3Y)(%) is ranked lower than
52% of the 234 Companies
in the Global Medical Devices industry.

( Industry Median: 3.70 vs. NUVA: 3.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NUVA' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -40.2  Med: 13.60 Max: 480.7
Current: 3.4
-40.2
480.7
EBITDA Growth (3Y)(%) 24.40
NUVA's EBITDA Growth (3Y)(%) is ranked higher than
82% of the 199 Companies
in the Global Medical Devices industry.

( Industry Median: 1.90 vs. NUVA: 24.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NUVA' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -41.20 Max: 104.5
Current: 24.4
0
104.5
EPS Growth (3Y)(%) 161.20
NUVA's EPS Growth (3Y)(%) is ranked higher than
97% of the 201 Companies
in the Global Medical Devices industry.

( Industry Median: 2.60 vs. NUVA: 161.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NUVA' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -66.3  Med: -31.40 Max: 161.2
Current: 161.2
-66.3
161.2
» NUVA's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-07-28)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

NUVA Guru Trades in Q2 2015

Mario Gabelli 163,030 sh (+1.14%)
PRIMECAP Management 901,000 sh (unchged)
Vanguard Health Care Fund Sold Out
Steven Cohen Sold Out
Louis Moore Bacon Sold Out
Ken Fisher 1,524,332 sh (-1.93%)
Jim Simons 273,488 sh (-31.04%)
Paul Tudor Jones 5,600 sh (-64.30%)
» More
Q3 2015

NUVA Guru Trades in Q3 2015

RS Investment Management 149,540 sh (New)
Joel Greenblatt 16,861 sh (New)
Steven Cohen 7,400 sh (New)
Paul Tudor Jones 8,905 sh (+59.02%)
PRIMECAP Management 901,000 sh (unchged)
Mario Gabelli 162,910 sh (-0.07%)
Ken Fisher 1,414,482 sh (-7.21%)
Jim Simons 248,388 sh (-9.18%)
» More
Q4 2015

NUVA Guru Trades in Q4 2015

John Paulson 31,800 sh (New)
Steven Cohen 219,900 sh (+2871.62%)
RS Investment Management 753,190 sh (+403.67%)
Joel Greenblatt 26,602 sh (+57.77%)
Jim Simons 286,588 sh (+15.38%)
Mario Gabelli 166,150 sh (+1.99%)
PRIMECAP Management 901,000 sh (unchged)
Samuel Isaly 806,000 sh (unchged)
Paul Tudor Jones Sold Out
Ken Fisher 1,403,598 sh (-0.77%)
» More
Q1 2016

NUVA Guru Trades in Q1 2016

Pioneer Investments 33,834 sh (New)
Paul Tudor Jones 21,787 sh (New)
Steven Cohen 674,900 sh (+206.91%)
RS Investment Management 1,031,723 sh (+36.98%)
Mario Gabelli 170,000 sh (+2.32%)
Ken Fisher 1,410,780 sh (+0.51%)
PRIMECAP Management 901,000 sh (unchged)
Samuel Isaly 806,000 sh (unchged)
Joel Greenblatt Sold Out
John Paulson Sold Out
Jim Simons 260,200 sh (-9.21%)
» More
» Details

Insider Trades

Latest Guru Trades with NUVA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices
Compare:NAS:IART, OTCPK:EKTAY, OTCPK:GGNDF, NAS:MASI, OTCPK:SHWGF, NAS:LIVN, OTCPK:NHNKY, NYSE:GMED, NYSE:NVRO, NYSE:PEN, NAS:WMGI, OTCPK:FSPKF, NAS:ABMD, OTCPK:IOBCF, NAS:CNMD, NAS:BABY, NAS:CYNO, NAS:LDRH, NAS:ZLTQ, OTCPK:BSNRF » details
Traded in other countries:NK8.Germany,
NuVasive Inc is a medical device company. The Company develops minimally-disruptive surgical products and procedurally-integrated solutions for the spine. Its currently-marketed product portfolio is focused on applications for spine fusion surgery.

NuVasive Inc was incorporated in Delaware on July 21, 1997, and began commercializing its products in 2001. It is a medical device company engaged in developing minimally disruptive surgical products and procedures for the spine. The Company's current-marketed product portfolio is engaged in applications for spine fusion surgery, including biologics. The Company's product offering includes a minimally disruptive surgical platform called Maximum Access Surgery, or MAS. The MAS platform combines three categories of solutions that collectively minimize soft tissue disruption during spine fusion surgery, provide maximum visualization and are designed to enable safe and reproducible outcomes for the surgeon and the patient. The platform includes its proprietary software-driven nerve detection and avoidance systems, NVM5 and NVJJB, and Intra-Operative Monitoring (IOM) support; MaXcess, an integrated split-blade retractor system; and a variety of specialized implants. The Company's primary business model is to loan its MAS systems to surgeons and hospitals that purchase implants, biologics and disposables for use in individual procedures. In addition, for larger customers, the Company's proprietary nerve monitoring systems, MaXcess and surgical instrument sets are placed with hospitals for an extended period at no up-front cost to them. The Company also offers a range of bone allograft in patented saline packaging, disposables and spine implants, which include its branded CoRoent products and fixation devices such as rods, plates and screws. Implants, biologics and disposables are shipped from the Company's inventories. The Company sells an immaterial quantity of MAS instrument sets, MaXcess and nerve monitoring systems to hospitals. Its spine surgery product line offerings, which include products for the thoracolumbar and the cervical spine, are used to enable access to the spine and to perform restoration and fusion procedures in a minimally disruptive fashion. In the United States, it currently sells its products through a combination of exclusive independent sales agencies and directly-employed sales shareowners. The Company has approximately 230 issued U.S. patents, 165 foreign national patents, and 284 pending patent applications. The Company's competitors are Medtronic Sofamor Danek (Medtronic), DePuy/Synthes, a Johnson & Johnson company, Stryker Spine, Globus Medical, Biomet Spine, and Zimmer Spine. It also faces competition from physician owned distributorships (PODs), which are medical device distributors that are owned, directly or indirectly, by physicians. The Company's products,medical devices and tissues subject to regulation by the FDA and other regulatory bodies.

Ratios

vs
industry
vs
history
P/E(ttm) 124.42
NUVA's P/E(ttm) is ranked lower than
92% of the 168 Companies
in the Global Medical Devices industry.

( Industry Median: 26.63 vs. NUVA: 124.42 )
Ranked among companies with meaningful P/E(ttm) only.
NUVA' s P/E(ttm) Range Over the Past 10 Years
Min: 14.88  Med: 82.15 Max: 347.16
Current: 124.42
14.88
347.16
Forward P/E 39.68
NUVA's Forward P/E is ranked lower than
87% of the 54 Companies
in the Global Medical Devices industry.

( Industry Median: 24.15 vs. NUVA: 39.68 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 124.42
NUVA's PE(NRI) is ranked lower than
92% of the 168 Companies
in the Global Medical Devices industry.

( Industry Median: 26.92 vs. NUVA: 124.42 )
Ranked among companies with meaningful PE(NRI) only.
NUVA' s PE(NRI) Range Over the Past 10 Years
Min: 14.85  Med: 81.52 Max: 332.29
Current: 124.42
14.85
332.29
P/B 4.64
NUVA's P/B is ranked lower than
67% of the 297 Companies
in the Global Medical Devices industry.

( Industry Median: 2.74 vs. NUVA: 4.64 )
Ranked among companies with meaningful P/B only.
NUVA' s P/B Range Over the Past 10 Years
Min: 0.98  Med: 3.60 Max: 10.89
Current: 4.64
0.98
10.89
P/S 3.70
NUVA's P/S is ranked lower than
56% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 2.99 vs. NUVA: 3.70 )
Ranked among companies with meaningful P/S only.
NUVA' s P/S Range Over the Past 10 Years
Min: 0.85  Med: 3.15 Max: 10.54
Current: 3.7
0.85
10.54
PFCF 58.89
NUVA's PFCF is ranked lower than
84% of the 95 Companies
in the Global Medical Devices industry.

( Industry Median: 29.37 vs. NUVA: 58.89 )
Ranked among companies with meaningful PFCF only.
NUVA' s PFCF Range Over the Past 10 Years
Min: 6.97  Med: 48.26 Max: 670.85
Current: 58.89
6.97
670.85
POCF 25.37
NUVA's POCF is ranked lower than
63% of the 130 Companies
in the Global Medical Devices industry.

( Industry Median: 19.79 vs. NUVA: 25.37 )
Ranked among companies with meaningful POCF only.
NUVA' s POCF Range Over the Past 10 Years
Min: 4.76  Med: 17.78 Max: 365.19
Current: 25.37
4.76
365.19
EV-to-EBIT 41.81
NUVA's EV-to-EBIT is ranked lower than
73% of the 167 Companies
in the Global Medical Devices industry.

( Industry Median: 20.28 vs. NUVA: 41.81 )
Ranked among companies with meaningful EV-to-EBIT only.
NUVA' s EV-to-EBIT Range Over the Past 10 Years
Min: -166  Med: 20.40 Max: 559.6
Current: 41.81
-166
559.6
EV-to-EBITDA 22.14
NUVA's EV-to-EBITDA is ranked lower than
64% of the 177 Companies
in the Global Medical Devices industry.

( Industry Median: 17.82 vs. NUVA: 22.14 )
Ranked among companies with meaningful EV-to-EBITDA only.
NUVA' s EV-to-EBITDA Range Over the Past 10 Years
Min: -320.9  Med: 14.10 Max: 4339.7
Current: 22.14
-320.9
4339.7
Current Ratio 5.40
NUVA's Current Ratio is ranked higher than
81% of the 314 Companies
in the Global Medical Devices industry.

( Industry Median: 2.88 vs. NUVA: 5.40 )
Ranked among companies with meaningful Current Ratio only.
NUVA' s Current Ratio Range Over the Past 10 Years
Min: 1.58  Med: 5.40 Max: 15.05
Current: 5.4
1.58
15.05
Quick Ratio 3.84
NUVA's Quick Ratio is ranked higher than
75% of the 314 Companies
in the Global Medical Devices industry.

( Industry Median: 2.09 vs. NUVA: 3.84 )
Ranked among companies with meaningful Quick Ratio only.
NUVA' s Quick Ratio Range Over the Past 10 Years
Min: 1.14  Med: 4.08 Max: 13.9
Current: 3.84
1.14
13.9
Days Inventory 309.48
NUVA's Days Inventory is ranked lower than
83% of the 282 Companies
in the Global Medical Devices industry.

( Industry Median: 136.99 vs. NUVA: 309.48 )
Ranked among companies with meaningful Days Inventory only.
NUVA' s Days Inventory Range Over the Past 10 Years
Min: 266.24  Med: 334.46 Max: 474.92
Current: 309.48
266.24
474.92
Days Sales Outstanding 55.19
NUVA's Days Sales Outstanding is ranked higher than
70% of the 271 Companies
in the Global Medical Devices industry.

( Industry Median: 68.67 vs. NUVA: 55.19 )
Ranked among companies with meaningful Days Sales Outstanding only.
NUVA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 52.35  Med: 58.06 Max: 75.34
Current: 55.19
52.35
75.34
Days Payable 12.21
NUVA's Days Payable is ranked lower than
94% of the 264 Companies
in the Global Medical Devices industry.

( Industry Median: 61.70 vs. NUVA: 12.21 )
Ranked among companies with meaningful Days Payable only.
NUVA' s Days Payable Range Over the Past 10 Years
Min: 12.75  Med: 27.90 Max: 67.96
Current: 12.21
12.75
67.96

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 3.33
NUVA's Price/Projected FCF is ranked lower than
71% of the 126 Companies
in the Global Medical Devices industry.

( Industry Median: 2.06 vs. NUVA: 3.33 )
Ranked among companies with meaningful Price/Projected FCF only.
NUVA' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.2  Med: 2.50 Max: 18.72
Current: 3.33
1.2
18.72
Price/Median PS Value 1.17
NUVA's Price/Median PS Value is ranked lower than
57% of the 268 Companies
in the Global Medical Devices industry.

( Industry Median: 1.02 vs. NUVA: 1.17 )
Ranked among companies with meaningful Price/Median PS Value only.
NUVA' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.3  Med: 0.97 Max: 2.8
Current: 1.17
0.3
2.8
Earnings Yield (Greenblatt) (%) 2.42
NUVA's Earnings Yield (Greenblatt) (%) is ranked higher than
61% of the 308 Companies
in the Global Medical Devices industry.

( Industry Median: 0.90 vs. NUVA: 2.42 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
NUVA' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.2  Med: 2.30 Max: 6.8
Current: 2.42
0.2
6.8

More Statistics

Revenue (TTM) (Mil) $833.8
EPS (TTM) $ 0.48
Beta0.64
Short Percentage of Float8.00%
52-Week Range $36.81 - 60.09
Shares Outstanding (Mil)49.83

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 929 1,005 1,090
EPS ($) 1.48 1.94 2.34
EPS w/o NRI ($) 1.48 1.94 2.34
EPS Growth Rate
(3Y to 5Y Estimate)
17.90%
» More Articles for NUVA

Headlines

Articles On GuruFocus.com
Most-Bought Small Cap Stocks During 4th Quarter Mar 28 2016 
Weekly CEO Buys Highlight: BRKR, GAIN, LUB, NUVA, FGP Jun 21 2015 
Weekly CEO Buys Highlight: TPC, GBDC, NUVA, TEGP, JOY Jun 14 2015 
Weekly CEO Buys Highlight: TPC, NUVA, PHII, GBDC, ARO Jun 10 2015 
Weekly CEO Buys Highlight: NUVA, HK, BKFS, PODD, CLF Jun 02 2015 
Guru Fisher Cuts NUVA - Medical Insurance Resists NuVasive Procedure Apr 11 2013 
NuVasive Inc. (NUVA) President and COO Keith Valentine sells 2,015 Shares Jan 25 2011 
Weekly Guru Bargains Highlights: ASIA , SAY , VRX , AMLN , NUVA Jan 09 2011 
Weekly Guru Bargains Highlights: ASIA, SAY, VRX, AMLN, NUVA Jan 01 2011 
Three Stocks for 2011: NUVA, ENOC, CBK Nov 25 2010 

More From Other Websites
NuVasive settles spinal surgery patent fight with Medtronic Jun 30 2016
[$$] NuVasive to Settle Patent Dispute With Medtronic Jun 30 2016
NUVASIVE INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 30 2016
4:05 pm NuVasive settles ongoing patent litigation with Medtronic (Jun 30 2016
NuVasive Announces Conference Call and Webcast of Second Quarter 2016 Results Jun 29 2016
NuVasive Announces Conference Call and Webcast of Second Quarter 2016 Results Jun 29 2016
4 Medical Device Makers With Healthy-Looking Charts Jun 29 2016
Zimmer's LDR Deal Could Force Others to Grow a Dealmaking Spine Jun 24 2016
Why NuVasive (NUVA) Could Beat Earnings Estimates Again Jun 10 2016
NuVasive Rises on High Trading Volumes Jun 10 2016
M&A Drives Up Spinal Stocks LDR, NuVasive, Globus Medical Jun 07 2016
Cramer Says Buy NuVasive on Heels of Zimmer's LDR Deal Jun 07 2016
Jim Cramer: Zimmer-LDR Deal Is Great Jun 07 2016
NuVasive to Strengthen Spine Service Line with Biotronic Buy Jun 07 2016
NuVasive to Acquire Biotronic NeuroNetwork Jun 06 2016
NUVASIVE INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial... Jun 06 2016
NuVasive to Acquire Biotronic NeuroNetwork Jun 06 2016
Cramer’s Exec Cut: Why you might hear about more cyber br... Jun 03 2016
NuVasive, Inc. :NUVA-US: Earnings Analysis: Q1, 2016 By the Numbers : June 3, 2016 Jun 03 2016
Moving Average Crossover Alert: NuVasive (NUVA) Jun 03 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)